Clinical Trials in France / NCT07881055
Starting soon
Observational
Cryptococcosis Associated With Bruton Tyrosine Kinase Inhibitors
NCT07881055 · tracked via the Priya Life Science France tracker
Condition(s) studied
Cryptococcosis
Study summary
The purpose of this study is to describe the clinical, biological, and radiographic characteristics at the time of cryptococcosis diagnosis, as well as the time interval between the initiation of BTK inhibitor therapy and the diagnosis of cryptococcosis.
And also, the clinical course of each patient at 12 months in order to evaluate the susceptibility to cryptococcosis correlated with BTK inhibitor therapy.
Eligibility
Inclusion Criteria:
* Adult patient (≥18 years old)
* Patient with a diagnosis of microbiologically documented cryptococcosis (antigen, direct examination, culture) established between January 2013 and January 2024 by the clinicians treating the patient with a BTK inhibitor (BTKi)\*.
* Cryptococcosis diagnoses will be validated by infectious disease expert (Prof. Fanny Lanternier, Dr. Olivier Paccoud) based on information provided by the clinicians treating the patient.
Exclusion Criteria:
* Patient objecting to the use of their data.
* Patient under legal guardianship or curatorship.
* Patient unable to provide free and informed consent.
Primary outcome measure(s)
- Clinical manifestations description of cryptococcosis — 1 day
Number of clinical manifestations and description of cryptococcosis at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. - Infection sites of cryptococcosis — 1 day
Type of infection sites in cryptococcosis patients at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. - Microbiological and mycological data description of cryptococcosis — 1 day
Microbiological and mycological data in cryptococcosis patients at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. - Biological parameters of cryptococcosis — 1 day
Biological parameters of cryptococcosis at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Necker - Enfants Malades | Paris | Paris |
More Assistance Publique - Hôpitaux de Paris trials in France
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07881055 on ClinicalTrials.gov ↗ ← All trials in France